ArticleArchives of rehabilitation research and clinical translation2025
Evaluation of Clemastine's Effects on Clinical and Electrodiagnostic Parameters in Individuals With CTS: A Preliminary Placebo-Controlled Double-Blind RCT.
Article in Archives of rehabilitation research and clinical translation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Author Response to Letter to the Editor: Evaluation of Clemastine Effects on Clinical and Electrodiagnostic Parameters in Carpal Tunnel Syndrome (CTS) Patients: A Preliminary Placebo-Controlled Double Blind RCT.Archives of rehabilitation research and clinical translation · 2026Article
- Letter to the Editor: Evaluation of Clemastine's Effects on Clinical and Electrodiagnostic Parameters in Individuals With CTS: A Preliminary Placebo-Controlled Double-Blind RCT.Archives of rehabilitation research and clinical translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy of clemastine in improving clinical and electrophysiological outcomes in patients with carpal tunnel syndrome (CTS) when combined with standard splint therapy. Design: A double-blind, randomized, placebo-controlled trial with follow-up assessments at 1 and 3 months. Setting: A physical medicine and rehabilitation outpatient clinic. Participants: Adult patients (N=27) (mean age=46.4y; sex ratio, 29.2% men and 70.8% women), enrolled with electrodiagnostically confirmed mild to moderate CTS, were randomized into clemastine (n=14) and placebo (n=13) groups. Interventions: The treatment group received 1 mg oral clemastine nightly plus a wrist splint, while the control group received a placebo plus an identical wrist splint, with both interventions maintained for 3 months. Main Outcome Measures: Primary endpoints included Boston Carpal Tunnel Questionnaire Symptom Severity (BQ-SS) and Functional Status (BQ-FS) scores, nerve conduction study parameters (median nerve sensory and motor distal latency), and ultrasonographic median nerve cross-sectional area. Results: The case group showed a significant difference in follow-up mean BQ-FS and BQ-SS scores (ANOVA, Conclusions: Clemastine, combined with wrist splinting, may provide further clinical benefits in patients with CTS, particularly in improving BQ-SS and BQ-FS outcomes. Further research is necessary to confirm these findings and explore appropriate dosing options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.